CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 58 enrolled / 58 target
Drug / intervention
Abaloparatidedrug
Likely dose
80 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04167163
NCT04167163Phase 4CompletedOn Track (0.8/mo)Completion was 14mo ago
CompareCT.gov

An Open-Label Phase 2 Study of Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty

University of Wisconsin, Madison·interventional·Posted Nov 18, 2019·Updated Jun 5, 2026

In Brief

A Phase 4 clinical trial evaluating Abaloparatide for Osteoporosis and Arthroplasties, Knee Replacement. Completed, enrolled 58 participants across 1 site.

Detailed Summary

The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Arthroplasties, Knee Replacement
CountriesUnited States
CollaboratorsRadius Health, Inc.

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedNov 18, 2019
Enrollment StartJan 10, 2020
Primary CompletionApr 3, 2025
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 6.6 years ago

Arms & Interventions

Treatment groupactive_comparator

Those with clinical osteoporosis who elect ABL treatment. ABL therapy will begin 3 months pre-TKA and continue for a total of 18 months. ABL will be administered by injection pen with dose of 80 mcg SC qDay.

Drug: Abaloparatide
Comparator groupno_intervention

Those with clinical osteopenia who receive no treatment.

Interventions

Abaloparatidedrug

18 month ABL treatment